AZ expanding Maryland biologics center; Valeant eyes securities buyback;

@FiercePharma: #FDA approves Purdue's abuse-resistant Hysingla, a hydrocodone pill aimed at knocking off Zohydro. Story | Follow @FiercePharma

@CarlyHFierce: #ICYMI yesterday - Themis, Institut Pasteur expand collaboration on solid PhI Chikungunya results. | Follow @CarlyHFierce

> AstraZeneca ($AZN) is socking $200 million-plus into expansions at its Frederick, MD biologics manufacturing center. Release

>Valeant Pharmaceuticals ($VRX) says it could buy back up to $2 billion worth of securities just days after losing a bid to acquire Allergan. Report

> The Washington Post calls Pfizer's ($PFE) failed bid for AstraZeneca the year's "biggest financial turkey." More

Medical Device News

@FierceMedDev: InfoBionic gets $17M to offer cloud-based cardiac monitoring. Story | Follow @FierceMedDev

@StacyALawrence: Second Sight IPO pops 122% in first day. That's 8th largest IPO pop this year in any sector. See my updated story. | Follow @StacyALawrence

@VarunSaxena2: Smith & Nephew closes U.S. facility, sells another in U.K. with 100+ to be laid off $SNN. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FierceDiagnostics: Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article | Follow @EmilyWFierce

> Gates Foundation backs Ebola trials for plasma-based and other treatments. Article

> Tandem partners for open-source software to improve insulin pump data access. More

> Boston Scientific ordered to hand over $18.5M in vaginal mesh litigation. Story

Biotech News

@FierceBiotech: EuroBiotech Report: U.K. starts ambitious drug dev review, Onxeo to raise €41.6M, Galapagos mulls Nasdaq listing. More | Follow @FierceBiotech

@JohnCFierce: 5 of the top 10 biotech news stories of the year so far in FierceBiotech are on immuno-oncology. Oh, my. | Follow @JohnCFierce

@DamianFierce: $ABBV's hep C combo will be branded as Viekirax + Exviera (at least in Europe). More from the EMA | Follow @DamianFierce

> Beware sketchy biotechs with big plans for Ebola, SEC says. Article

> AbbVie gets an EU green light for its next-gen hep C treatment. More

> Purdue wins a pain pill approval with Zohydro in its crosshairs. News

And Finally... Bloomberg takes a look at the code names used during the Valeant-Allergan ($AGN)-Actavis ($ACT) takeover battle, including Valeant's "Project Olympus" and Actavis' "Project Fruit Basket." More

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.